Recombinant Human B7-2/CD86 Protein (HEK293)，Avi & His

B7-2, also known as CD86, is a crucial co-stimulatory molecule involved in the regulation of immune responses, primarily participating in T-cell activation. It is primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. The interaction of B7-2/CD86 with its receptor CD28 on T cells provides essential signals for T-cell activation and survival, thereby playing a key role in the adaptive immune response. Research into B7-2/CD86 has gained significant interest due to its implications in various immunological disorders, including autoimmune diseases, cancer, and transplant rejection. In cancer immunotherapy, B7-2/CD86 is being explored as a potential target for enhancing anti-tumor responses, as its expression can influence the efficacy of immune checkpoint inhibitors. Moreover, recombinant B7-2/CD86 proteins are being developed to understand their structural and functional properties, which could lead to novel therapeutic strategies aimed at modulating immune responses. By elucidating the molecular mechanisms of B7-2/CD86 interactions with T cells, researchers aim to design innovative approaches to either stimulate or suppress immune responses in a controlled manner, paving the way for advancements in vaccination strategies and immunotherapy applications. Thus, the study of B7-2/CD86 recombinant proteins not only enhances our understanding of immune regulation but also holds promise for developing new therapeutic modalities to treat various diseases where the immune system plays a pivotal role.